Resonance Health Ltd ( (AU:RHT) ) has provided an update.
Resonance Health Ltd reported a significant financial performance for the first half of FY25, with a 60% increase in revenue to $5.2 million and a 35% rise in normalised operating EBITDA to $0.54 million. The company’s free cash flow surged by 353% to $0.9 million, indicating strong operational efficiency and financial health, potentially enhancing its industry positioning and stakeholder confidence.
More about Resonance Health Ltd
Resonance Health Ltd operates in the healthcare industry, focusing on medical imaging software and services. The company specializes in providing diagnostic imaging solutions, particularly for liver disease assessment, and is known for its innovative technology and market focus on improving patient outcomes.
YTD Price Performance: 16.00%
Average Trading Volume: 247,167
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$26.66M
Learn more about RHT stock on TipRanks’ Stock Analysis page.